[A new, more expensive agent against ovarian cancer. Worth its price?].
Högberg
T
T
Gynekologisk onkologi, Universitetssjukhuset i Lund.
Karlsson
G
G
Ridderheim
M
M
Boman
K
K
Frankendal
B
B
Horvath
G
G
Sorbe
B
B
Strang
P
P
Rosenberg
P
P
D000972:Antineoplastic Agents, Phytogenic / Q000191:economics / Q000627:therapeutic use*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000523:psychology; D017239:Paclitaxel / Q000191:economics / Q000627:therapeutic use*; D011788:Quality of Life; D013548:Sweden
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel
Nytt, dyrare medel mot ovarialcancer. Ar det värt sitt pris?